|
The 2023-2024 AVP provider agreement is due August 14, 2023 for providers wishing to request any of the routine vaccines listed here. A link to request these vaccines will ONLY be sent to providers who have a provider agreement on file in Redcap for their facility by the deadline of August 14, 2023. Please remember that existing providers must re-enroll annually to participate and request vaccine.
Please note this important update: The August 14th deadline noted above is for all providers who wish to obtain non-COVID-19 and non-flu vaccines through AVP. Any provider who misses the August 14th deadline will still have the opportunity to enroll in the Adult Vaccine Program to request COVID-19 and flu vaccines.
Here is a summary of this information:
 The next order request opportunity for routine AVP vaccine will be in February/March 2024.
-
1. Patient Eligibility: Eligibility for the AVP has changed:
-
2. Eligibility documentation: Eligibility screening and documentation will be required for all patients receiving AVP vaccine. Eligibility documentation can be completed electronically in the patient’s medical record, in the IIS, or in this provided patient eligibility screening form
-
3. Site visits will be required for providers newly enrolled in AVP due to new federal guidelines. Providers who were previously enrolled in AVP will not need a site visit at this time. Additional details to come.
 ACIP provides recommendations for “Use of Respiratory Syncytial Virus Vaccines in Older Adults” in MMWR.
In June ACIP voted to recommend RSV vaccination for Adults ages 60 years or older using shared clinical decision-making. They recently published Use of Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices—United States, 2023 in the MMWR last week to provide some guidance on considerations when assessing for the need to vaccinate.
The article further explains what points to consider when assessing the need for RSV vaccination in an Adult age 60 or older:
“ …providers and patients should consider the patient’s risk for severe RSV-associated disease. Epidemiologic evidence indicates that persons aged ≥60 years who are at highest risk for severe RSV disease and who might be most likely to benefit from vaccination include those with chronic medical conditions such as lung diseases, including chronic obstructive pulmonary disease and asthma; cardiovascular diseases such as congestive heart failure and coronary artery disease; moderate or severe immune compromise (either attributable to a medical condition or receipt of immunosuppressive medications or treatment); diabetes mellitus; neurologic or neuromuscular conditions; kidney disorders, liver disorders, and hematologic disorders; persons who are frail; persons of advanced age; and persons with other underlying conditions or factors that the provider determines might increase the risk for severe RSV-associated respiratory disease. Adults aged ≥60 years who are residents of nursing homes and other long-term care facilities are also at risk for severe RSV disease. It should be noted that the numbers of persons enrolled in the trials who were frail, were of advanced age, and lived in long-term care facilities were limited, and persons with compromised immunity were excluded (some of whom might have an attenuated immune response to RSV vaccination). However, adults aged ≥60 years in these populations may receive vaccination using shared clinical decision-making given the potential for benefit.”
Please note that the Adult Vaccine Program will be unable to provide RSV vaccine during the current budget year.
|
